Core Viewpoint - Investors in the Medical - Biomedical and Genetics sector should consider Exelixis (EXEL) and Exact Sciences (EXAS) for potential value opportunities, with a closer examination needed to determine which stock offers better value [1] Valuation Metrics - Exelixis has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision trend compared to Exact Sciences, which has a Zacks Rank of 3 (Hold) [3] - The forward P/E ratio for EXEL is 13.46, significantly lower than EXAS's forward P/E of 73.35, suggesting EXEL may be undervalued [5] - EXEL's PEG ratio is 0.69, while EXAS has a PEG ratio of 2.42, indicating that EXEL's expected earnings growth is more attractive relative to its price [5] - EXEL has a P/B ratio of 5.41 compared to EXAS's P/B of 7.76, further supporting EXEL's more favorable valuation metrics [6] Investment Conclusion - Given the stronger estimate revision activity and more attractive valuation metrics, EXEL is positioned as the superior option for value investors at this time [7]

Core Insights - Adagene Inc. announced an update on its ongoing Phase 1b/2 study of muzastotug in combination with pembrolizumab for patients with microsatellite stable metastatic colorectal cancer (MSS CRC), with data expected in Q1 2026 [1][6] - The company reported unaudited cash and cash equivalents of $74.5 million as of December 31, 2025, which is anticipated to provide sufficient runway until late 2027 [1][3] 2025 Key Accomplishments - The company demonstrated a favorable safety profile for muzastotug at doses 10-20 times higher than first-generation CTLA-4 inhibitors, with encouraging overall response rates and durable responses [5] - Muzastotug received FDA Fast Track designation for use in combination with KEYTRUDA for adult patients with MSS CRC without current or active liver metastases [5] - Adagene secured a strategic investment of up to $25 million from Sanofi to support the randomized Phase 2 study of muzastotug [5] - Collaborations were established with Third Arc Bio for developing next-generation T cell therapies and with Exelixis for advancing a third masked ADC against a solid tumor target [5] 2026 Objectives - The company aims to provide a data update from the ongoing Phase 1b/2 study, including results from 41 patients in the 10 mg/kg cohort and 26 patients in the 20 mg/kg cohort [6] - Complete enrollment of the randomized Phase 2 dose-optimization study with muzastotug, aligned with FDA Project Optimus [6] - Share results from a clinical trial collaboration with Roche evaluating muzastotug in combination with atezolizumab and bevacizumab for liver cancer [6] Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies using computational biology and artificial intelligence [8] - The company's lead clinical program, muzastotug, is a masked anti-CTLA-4 SAFEbody targeting regulatory T cells in the tumor microenvironment, currently in Phase 1b/2 and Phase 2 studies [10]

Core Viewpoint - Exelixis, Inc. (EXEL) is perceived to have significant growth potential that is not being adequately recognized in the market [1]. Group 1: Company Overview - Exelixis, Inc. is highlighted as a company with one of the highest growth potentials in the medium term [1]. Group 2: Analyst Background - The analyst has over six years of experience in the investment sector, with a background in equity analysis across various industries [1]. - The analyst's educational qualifications include a bachelor's degree from Antwerp, a master's from KU Leuven, and an MBA in Finance from Vlerick [1]. Group 3: Investment Focus - The analyst is currently building an investment project focused on the CIS region, applying Western analytical tools to identify hidden value in emerging markets [1].

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are significant, with data centers consuming as much energy as small cities, leading to concerns about power grid capacity and rising electricity prices [2][3] Investment Opportunity - A specific company is highlighted as a critical player in the AI energy sector, owning essential energy infrastructure assets that are poised to benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is positioned as a "toll booth" operator in the AI energy boom, collecting fees from energy exports [5][6] Financial Position - The company is noted for being debt-free and holding a substantial cash reserve, which is nearly one-third of its market capitalization, providing a strong financial foundation [8] - It is trading at less than 7 times earnings, indicating a potentially undervalued investment opportunity compared to its peers in the energy and utility sectors [10] Market Trends - The company is strategically aligned with several market trends, including the onshoring boom driven by tariffs, a surge in U.S. LNG exports, and a unique position in nuclear energy [14][7] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, further solidifying the importance of investing in AI-related infrastructure [12] Future Outlook - The potential for significant returns is emphasized, with projections suggesting a possible 100% return within 12 to 24 months for investors who act now [15][19] - The company is positioned to capitalize on the disruption caused by AI, which is reshaping traditional industries and creating new investment opportunities [11][12]

Group 1 - Exelixis is the final presenting company at the 44th Annual JPMorgan Healthcare Conference [1] - The presentation will be led by President and CEO Michael Morrissey [1][2]

Summary of Exelixis Conference Call Company Overview - **Company**: Exelixis - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Presenter**: Michael Morrissey, President and CEO Key Industry Insights - **Focus on Oncology**: Exelixis is dedicated to improving cancer treatment through innovative therapies, particularly in solid tumors, leveraging their expertise in biology, pharmacology, and clinical sciences [4][5][6] - **Franchise Building**: The company emphasizes building multiple blockbuster franchises rather than focusing on single indications, aiming to maximize value for patients and shareholders [4][6][30] Financial Performance - **2025 Preliminary Results**: - Total revenues: $2.32 billion - Net product revenues: $2.123 billion - R&D expenses: approximately $825 million - Cash at year-end: $1.65 billion [13][14] - **2026 Guidance**: - Net product revenue expected between $2.325 billion and $2.425 billion, with a midpoint of $2.375 billion - R&D expenses projected between $875 million and $925 million [14][15] Product Pipeline and Growth Strategy - **Cabozantinib (Cabo)**: - Continues to be the primary revenue driver, maintaining its position as the top TKI in the U.S. for renal cell carcinoma (RCC) [7][13] - Cumulative growth of 30% from 2023 to 2025 [13] - **Zanzalitinib (Zanza)**: - Aiming to establish Zanza as a significant oncology franchise, with ongoing pivotal trials in RCC, colorectal cancer (CRC), and neuroendocrine tumors (NET) [9][10][29] - First regulatory filing for CRC submitted in Q4 2025 [9][15] - **Pipeline Expansion**: - Four molecules currently in clinical trials, with plans for additional investigational new drug (IND) applications [10][12] Market Opportunities - **Colorectal Cancer (CRC)**: - Identified as a fragmented market with a $1.5 billion opportunity, with strategies to position Zanza effectively against competitors [32][33] - **Neuroendocrine Tumors (NET)**: - Projected market growth from $2.5 billion to over $7 billion, with a focus on innovative therapies [29] Strategic Approach - **Combination Therapies**: - Emphasis on developing combination therapies that leverage different mechanisms of action to enhance treatment efficacy [24][25][26] - **Market Leadership**: - Aiming to establish leadership in multiple tumor types, including RCC and CRC, while focusing on improving patient outcomes and standard of care [17][22] Shareholder Returns - **Capital Allocation**: - $2.16 billion returned to shareholders through share repurchase programs since March 2023, with an ongoing $750 million program [12][30] Conclusion - Exelixis is strategically positioned to leverage its strong product pipeline and market insights to drive growth in the oncology sector, focusing on building franchises that enhance patient care and deliver shareholder value. The company is committed to disciplined capital allocation and innovative research to maintain its competitive edge in the market [30][38]

J.P. MORGAN 2026 HEALTHCARE CONFERENCE JANUARY 12, 2026 Building Next-Generation Oncology Franchises Michael M. Morrissey, Ph.D. President and CEO Safe Harbor Statement This presentation, including any oral presentation accompanying it, contains forward-looking statements, including, without limitation, statements related to: Exelixis' strategy to build franchises in key solid tumors; Exelixis' goal to become a leader in oncology R&D and a top 5 solid tumor oncology company, with multiple blockbuster produc ...

Financial Performance - Exelixis reported preliminary U.S. net product revenues of approximately $2.123 billion for fiscal year 2025[1]. - The company provided fiscal year 2026 net product revenues guidance of $2.325 billion to $2.425 billion[2]. - Total revenues for fiscal year 2025 are estimated at around $2.320 billion, with guidance for 2026 set at $2.525 billion to $2.625 billion[4]. - The effective tax rate for fiscal year 2026 is projected to be between 21% and 23%[4]. - Exelixis' preliminary financial results for FY 2025 are being finalized, with the company cautioning that these results are based on preliminary information and may differ from audited results[22]. Research and Development - Research and development expenses for fiscal year 2025 are approximately $825 million, with guidance for 2026 ranging from $875 million to $925 million[4]. - Exelixis anticipates continued growth in the cabozantinib franchise, which is the leading tyrosine kinase inhibitor in renal cell carcinoma and neuroendocrine tumors[8]. - The company expects to initiate the STELLAR-316 trial in mid-2026, evaluating zanzalintinib in patients with resected stage II/III colorectal cancer[14]. - Exelixis plans to advance two programs into clinical development in 2026, including LITESPARK-033 and STELLAR-201[14]. - The company is progressing XL309, XB010, XB628, and XB371 into full development as part of its strategy to build next-generation oncology franchises[21]. - The company is focused on advancing its pipeline, including the clinical development of XL557 and XB773, contingent on supportive phase 1 data[21]. Commercial Strategy - Exelixis anticipates 2026 to be a significant year for clinical, regulatory, and commercial progress, focusing on expanding its cabozantinib business and developing zanzalintinib[20]. - The company aims to establish lasting franchises in renal cell carcinoma (RCC), neuroendocrine tumors (NET), and colorectal cancer (CRC), while driving sustained growth and returning capital to shareholders[20]. - Exelixis expects continued strong commercial performance of cabozantinib, with anticipated growth in RCC and NET in 2026, including plans to expand its gastrointestinal (GI) sales team[20]. - The regulatory review process for zanzalintinib's NDA for previously metastatic CRC in combination with atezolizumab is underway, with potential first commercial launch planned[20]. - Exelixis plans to initiate several pivotal trials, including STELLAR-316 and STELLAR-301, in 2026, and expects clinical data readouts from STELLAR-303 and STELLAR-304[20]. - The company emphasizes the importance of maintaining adequate sales, marketing, and distribution capabilities for its products to ensure market acceptance[21]. Shareholder Returns - Exelixis has repurchased a total of $2.16 billion of its common stock since March 2023, retiring 76.7 million shares[16].

Core Insights - Exelixis, Inc. (EXEL) reported preliminary unaudited financial results for fiscal year 2025, with revenues of approximately $2.32 billion, slightly below the Zacks Consensus Estimate of $2.33 billion [2][8] - The company provided guidance for fiscal year 2026, projecting total revenues between $2.525 billion and $2.625 billion, driven by continued demand for its lead drug, Cabometyx [5][8] - Despite the positive outlook, the stock experienced a decline in pre-market trading on January 12, 2026 [1] Financial Performance - Preliminary net product revenues for 2025 were about $2.12 billion, with cash and marketable securities totaling $1.65 billion at year-end, indicating strong financial flexibility [4] - Research and development (R&D) expenses for 2025 were approximately $825 million, while selling, general and administrative (SG&A) expenses totaled around $520 million [4] 2026 Guidance - For 2026, net product revenues are expected to be in the range of $2.325 billion to $2.425 billion, reflecting a 3% price increase effective January 2026 [5][6] - Operating expenses are projected to rise, with R&D expenses estimated at $875 million to $925 million and SG&A expenses at $575 million to $625 million [6] Product Developments - Cabometyx continues to be a key growth driver, maintaining its position as the leading tyrosine kinase inhibitor (TKI) in renal cell carcinoma (RCC) [6][7] - The label expansion of Cabometyx to include treatment for pancreatic neuroendocrine tumors (pNET) and extra-pancreatic neuroendocrine tumors (epNET) is expected to boost sales further [3][7] Pipeline Expansion - Exelixis is actively expanding its oncology portfolio, with zanzalintinib being a significant near-term catalyst, currently under review for metastatic colorectal cancer (CRC) [10][11] - The company is also advancing several phase I assets, including XL309, XB010, XB628, and XB371, alongside plans for two new investigational new drug filings in 2026 [14][15] Shareholder Returns - Exelixis has repurchased $2.16 billion of stock since 2023, with an additional $750 million authorization in place through 2026, indicating a commitment to returning capital to shareholders [16] Market Performance - Exelixis shares have increased by 24.7% over the past year, outperforming the industry average gain of 19.6% [17]

Core Viewpoint - Exelixis anticipates significant clinical, regulatory, and commercial progress in 2026, focusing on expanding its cabozantinib business and developing zanzalintinib as a potential second commercial franchise while advancing its earlier-stage pipeline [1][19]. Financial Results and Guidance - Preliminary total revenues for fiscal year 2025 are approximately $2.320 billion, with guidance for fiscal year 2026 set between $2.525 billion and $2.625 billion [3]. - Net product revenues for fiscal year 2025 are approximately $2.123 billion, with guidance for fiscal year 2026 ranging from $2.325 billion to $2.425 billion [3]. - Cost of goods sold as a percentage of net product revenues is approximately 3.7% for 2025, with a projected range of 3.5% to 4.5% for 2026 [3]. - Research and development expenses for 2025 are approximately $825 million, with guidance for 2026 set between $875 million and $925 million [3]. - Selling, general, and administrative expenses for 2025 are approximately $520 million, with guidance for 2026 ranging from $575 million to $625 million [3]. - The effective tax rate for 2026 is projected to be between 21% and 23% [3]. Business Updates - The company is focused on leveraging its diverse pipeline and key clinical collaborations to build next-generation oncology franchises aimed at improving cancer care standards [1][6]. - Exelixis expects continued growth in its cabozantinib franchise, which is the leading tyrosine kinase inhibitor in renal cell carcinoma and neuroendocrine tumors [7]. - The company achieved major milestones with zanzalintinib, including a positive pivotal data readout and a U.S. regulatory filing for its use in metastatic colorectal cancer [6][8]. Regulatory and Clinical Milestones - The FDA is currently reviewing Exelixis' New Drug Application for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer [2][8]. - The STELLAR-303 trial for zanzalintinib has shown a statistically significant reduction in the risk of death compared to regorafenib, with further analyses expected in mid-2026 [8][9]. - The STELLAR-304 trial is evaluating zanzalintinib in combination with nivolumab versus sunitinib in previously untreated advanced non-clear cell renal cell carcinoma, with results anticipated in mid-2026 [10]. Pipeline Development - Exelixis is advancing several phase 1 clinical trials for new molecules, including XL309, XB010, XB628, and XB371, with plans to progress them into full development if data are supportive [12]. - The company anticipates initiating two new IND applications in 2026, further expanding its oncology pipeline [13]. Stock Repurchase Program - Exelixis has repurchased a total of $2.16 billion of its common stock since March 2023, with an additional $750 million authorized for repurchase before December 31, 2026 [15].